0.15Open0.15Pre Close0 Volume50 Open Interest30.00Strike Price0.00Turnover3480.92%IV81.85%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.0665Delta0.0220Gamma110.53Leverage Ratio-9.5842Theta0.0000Rho7.36Eff Leverage0.0002Vega
Grail Stock Discussion
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet